AGM Statement

Deltex Medical Group PLC
10 June 2003


10 June 2003


                            Deltex Medical Group plc

                 Annual General Meeting - Chairman's statement


Deltex Medical Group plc ('Deltex Medical'/'Group'/'Company'), the AIM listed
haemodynamic monitoring company will hold its Annual General Meeting at 12 noon
today.


In a statement to the meeting Deltex Medical's Chairman, Nigel Keen will say:


'Deltex Medical's opportunity and its goal is to make haemodynamic optimisation
guided by the CardioQ a standard of care in operating theatres, intensive care
units and accident and emergency departments worldwide. This will provide
doctors with information to enable them to guide therapy which will help them
make their patients better, quicker.


So far in 2003, Deltex Medical has continued to make progress in many areas.
The installed base has increased to nearly 1,000 CardioQ monitors around the
world.  A significant portion of the newly installed monitors are situated in
operating theatres, in particular in the UK, France and Italy, our best
developed markets.



The DP6 and DP12 probes launched in the UK last December have been positively
received and 30 hospitals have already bought either or both of these new
products for use in operating theatres.  In addition, there are a number of
other UK hospitals in the process of evaluating these probes with the CardioQ.



We are working closely with those doctors who have satisfied themselves of the
considerable economic as well as medical benefits of using our technology in
order to gather the data necessary to make compelling business cases for the
widespread adoption of the CardioQ in their hospitals.



Progress in the USA remains steady with an increasing amount of evidence that
doctors are beginning to pay more attention to minimally invasive means of
monitoring cardiac output.



The new pDP paediatric probe is being clinically evaluated in five of the six
major English paediatric hospitals with encouraging early results.  This month
we are launching the DP240 probe which is designed for use in longer term
monitoring of patients in intensive care departments; this probe is capable of
being placed via both the nose and the mouth.



The £1.3 million we raised in May from the issue of new shares has allowed us to
continue to invest aggressively in growing our business.'



Enquiries

Deltex Medical Group plc

Nigel Keen, Chairman

[e-mail]

01243 774 837



Andy Hill, Chief Executive

[e-mail]

01243 774 837



Ewan Phillips, Finance Director

[e-mail]

01243 774 837



Financial Dynamics

Stephanie Highett/Francetta Carr

[e-mail]

020 7831 3113







Notes for Editors



Deltex Medical primarily develops, assembles and markets a cardiac function
monitor and therapy guidance device, the CardioQ ('CardioQ'/'Monitor'). The
CardioQ incorporates the Company's proprietary software and a small diameter,
easy-to-use, minimally invasive, disposable oesophageal probe that is used for
transmitting and receiving an ultra-sound ('Doppler') signal. By using this
Doppler technology, the CardioQ provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.


There are nearly 1,000 CardioQs currently in use in hospitals worldwide and
distribution arrangements are in place in over 30 countries. In addition, there
are currently more than 75 clinical publications on the use of the CardioQ which
have repeatedly:-

  * validated the results of the Monitor against known standards for measuring
cardiac output, demonstrating that the technology works


  * proved that the CardioQ works in a wide range of surgical procedures


  * demonstrated that the Company's technology provides significant health and
economic benefits by helping to reduce post-operative complications and length
of hospital stays by an average of 30 to 40 per cent for a wide range of
patients.

The Company is also currently developing a number of new products:-

  * the SupraQ - a monitor based on the CardioQ technology but using a
completely non-invasive probe; the prototype is being prepared for clinical
testing


  * the NeuroQ - a monitor designed to measure blood flow in the brain; the new
prototype is in preparation for clinical trials.


                      This information is provided by RNS
            The company news service from the London Stock Exchange